Brucellosis Vaccine Market Forecasts to 2030 – Global Analysis By Vaccine Type (DNA Vaccine, Subunit Vaccine and Other Vaccine Types), Disease (Viral Diseases, Bacterial Vaccines and Other Diseases), Distribution Channel, Application, End User and By Geog

Brucellosis Vaccine Market Forecasts to 2030 – Global Analysis By Vaccine Type (DNA Vaccine, Subunit Vaccine and Other Vaccine Types), Disease (Viral Diseases, Bacterial Vaccines and Other Diseases), Distribution Channel, Application, End User and By Geography

According to Stratistics MRC, the Global Brucellosis Vaccine Market is accounted for $239.6 million in 2023 and is expected to reach $377.4 million by 2030 growing at a CAGR of 6.70% during the forecast period. The Brucellosis vaccine is a preventive measure against Brucella bacteria, which cause brucellosis—a zoonotic disease affecting animals and humans. The vaccine is primarily administered to livestock such as cattle, goats, and sheep, as these animals are common reservoirs for the bacteria. The vaccine helps control the spread of brucella infections, reducing the risk of transmission to humans through contact with contaminated animal products or direct contact with infected animals.

According to the report of the United States Department of Agriculture (USDA), there were about 91.9 million cattle and calves in the United States. Similarly, report of the USDA, the population of cattle in India is expected to increase and reach 306.7 million in 2022.

Market Dynamics:

Driver:

Prevalence of brucellosis

With Brucellosis posing substantial health and economic threats globally, particularly in regions with close human-animal interaction, the demand for effective vaccines has risen. Governments, livestock owners, and healthcare authorities are increasingly recognizing the importance of prevention through vaccination to control the spread of Brucellosis. This heightened awareness, coupled with a growing need for sustainable agricultural practices, fuels the expansion of the brucellosis vaccine market as stakeholders actively seek and invest in innovative vaccine solutions to mitigate the impact of this infectious disease.

Restraint:

Antimicrobial treatment options

Antimicrobial treatment options play a crucial role in the restraint of the Brucellosis vaccine market. Antibiotics such as doxycycline and rifampin are essential for managing and treating the infection in humans. This reliance on antimicrobial therapies may hinder the growth of the Brucellosis vaccine market, as effective drugs can provide immediate relief and may reduce the perceived need for preventive vaccination. Additionally, challenges in developing a universally effective brucellosis vaccine further emphasize the significance of antimicrobial treatments in addressing the current burden of the disease.

Opportunity:

Growing livestock industry

As the demand for meat and dairy products rises globally, livestock farmers are keen on ensuring the health and productivity of their herds. Brucellosis can cause reproductive issues in cattle and sheep, leading to economic losses in the industry. The development and widespread adoption of effective Brucellosis vaccines offer a preventive solution, reducing the prevalence of the disease and promoting overall livestock well-being. This presents a lucrative market for vaccine manufacturers, as farmers increasingly prioritize disease management to enhance the sustainability and profitability of their livestock operations.

Threat:

Limited awareness and education

The limited awareness and education threat in the Brucellosis vaccine market arises from insufficient knowledge and understanding among stakeholders, including healthcare professionals and the public. This lack of awareness may hinder the adoption of brucellosis vaccines, leading to lower vaccination rates. Inadequate education about the severity of brucellosis and the benefits of vaccination can contribute to an underestimation of the disease's impact, potentially impeding efforts to control its spread. Addressing this threat requires targeted educational campaigns to enhance awareness among healthcare providers, policymakers, and the general population.

Covid-19 Impact:

The diversion of resources and focus towards combating the global health crisis has led to a slowdown in the development, production, and distribution of brucellosis vaccines. Research and investment priorities have shifted, affecting the overall progress and availability of vaccines for Brucellosis. Additionally, disruptions in supply chains and logistical challenges have further hindered vaccine accessibility. As efforts continue to address COVID-19, the Brucellosis vaccine market faces delays and uncertainties, potentially affecting the control of this bacterial infection in both human and animal populations.

The viral diseases segment is expected to be the largest during the forecast period

The viral diseases segment is experiencing notable growth due to increasing awareness and efforts to combat this bacterial infection. And encompassing innovative research and development targeting Brucella strains, has witnessed a surge in investment and advancements. Furthermore, this growth is driven by a collaborative approach between pharmaceutical companies, research institutions, and governmental initiatives to address the significant public health concern posed by brucellosis.

The animal care centers segment is expected to have the highest CAGR during the forecast period

The Animal Care Centers segment is experiencing notable growth due to increasing awareness and proactive measures taken to control the spread of brucellosis in animals. With a rising emphasis on animal health and welfare, veterinary clinics and care centers are actively incorporating brucellosis vaccination programs into their services. This surge is also driven by regulatory efforts to mitigate the economic and public health impacts of brucellosis. Additionally, as livestock and companion animal owners seek preventive solutions, the demand for brucellosis vaccines within animal care centers is expanding.

Region with largest share:

North America dominated the global market and is expected to retain its position during the forecast period. Potential factors contributing to growth includes increased awareness about brucellosis prevention, rising demand for livestock health management, and government initiatives promoting animal health. The region's advanced veterinary healthcare infrastructure and research capabilities also foster the development and adoption of brucellosis vaccines. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

Region with highest CAGR:

The Asia Pacific is estimated to grow at a considerable growth rate in the market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China’s increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Increasing demand for dairy and meat products, coupled with a surge in animal husbandry practices, has fueled the need for effective vaccines.

Key players in the market

Some of the key players in Brucellosis Vaccine market include Biogenesis-Bago, Biovet, Boehringer Ingelheim, Calier, Ceva Sante Animale, Colorado Serum, CZ Veterinaria, Hester Biosciences, Indian Immunologicals, Onderstepoort Biological, Qilu, SYVA Laboratorios, Technovax and Zoetis.

Key Developments:

In January 2024, Ceva Santé Animale, acquired US-based Scout Bio, a biotech company focused on pet therapies. The move represents a significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Vaccine Types Covered:
• DNA Vaccine
• Subunit Vaccine
• Inactivated
• Live Attenuated
• mRNA Vaccines
• Vector Vaccine
• Viral vector vaccines
• Other Vaccine Types

Diseases Covered:
• Viral Diseases
• Bacterial Vaccines
• Allergy Vaccines
• Cancer Vaccines
• Other Diseases

Distribution Channels Covered:
• Hospital & Retail Pharmacies
• Government Suppliers
• Other Distribution Channels

Applications Covered:
• Cattle
• Goat
• Horses
• Sheep
• Swine
• Other Applications

End Users Covered:
• Veterinary Hospitals & Clinics
• Animal Care Centers
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements